Quince buys a rare disease biotech; Heron reduces headcount

Quince Ther­a­peu­tics will buy the pri­vate biotech Ery­Del SpA in a stock deal, with up to $485 mil­lion on the line in de­vel­op­ment, reg­u­la­to­ry and com­mer­cial biobucks.

Ery­Del stock­hold­ers will own about 16.7% of the com­bined com­pa­ny fol­low­ing the clos­ing, which is ex­pect­ed to oc­cur this quar­ter. Both boards have ap­proved it.

With the deal, Quince said it will have fund­ing to keep the lights on in­to 2026. Its $87.6 mil­lion will bankroll a Phase III clin­i­cal tri­al for Ery­Del’s lead as­set and an NDA sub­mis­sion, pend­ing study re­sults. Ery­Del’s Ery­Dex is be­ing test­ed for a rare pe­di­atric neu­ro­log­i­cal dis­ease known as atax­ia-telang­iec­ta­sia. There are no ap­proved treat­ments for the life-thread­ing con­di­tion, but re­searchers are look­ing in­to cus­tom gene ther­a­pies.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN